Source: ndtvprofit.com
Motilal Oswal expects 14% earnings CAGR over FY25-27E, led by 17% sales CAGR in Sun Pharma's specialty segment and 12% in DF/EM markets, and 160bp margin expansion.
Sun Pharma Is Well Poised To Sustain Growth In Focus Segments, Says Motilal Oswal Maintaining ‘Buy’
